5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 12,892 as of Wednesday, Nov. 28, 2012, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,435 issues advancing vs. 1,435 declining with 148 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.0%. On the negative front, top decliners within the sector include Herbalife ( HLF), down 2.7%, DaVita HealthCare Partners ( DVA), down 1.7%, Teva Pharmaceutical Industries ( TEVA), down 0.5% and Baxter International ( BAX), down 0.5%. Top gainers within the sector include Pfizer ( PFE), up 0.9%, UnitedHealth Group ( UNH), up 1.0% and Intuitive Surgical ( ISRG), up 0.9%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. HCA Holdings ( HCA) is one of the companies pushing the Health Care sector lower today. As of noon trading, HCA Holdings is down $0.25 (-0.8%) to $30.50 on light volume Thus far, 703,717 shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $30.33-$30.74 after having opened the day at $30.47 as compared to the previous trading day's close of $30.75.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. HCA Holdings has a market cap of $13.7 billion and is part of the health services industry. The company has a P/E ratio of 4.6, below the S&P 500 P/E ratio of 17.7. Shares are up 39.6% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and feeble growth in its earnings per share. Get the full HCA Holdings Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

4. As of noon trading, Cigna ( CI) is down $0.51 (-1.0%) to $51.91 on light volume Thus far, 577,048 shares of Cigna exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $51.70-$52.16 after having opened the day at $52.07 as compared to the previous trading day's close of $52.42.

CIGNA Corporation, a health services organization, through its subsidiaries, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $14.9 billion and is part of the health services industry. The company has a P/E ratio of 9.6, below the S&P 500 P/E ratio of 17.7. Shares are up 24.8% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Cigna a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cigna Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

3. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $1.42 (-0.8%) to $173.28 on light volume Thus far, 153,374 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 765,300 shares. The stock has ranged in price between $171.10-$174.57 after having opened the day at $173.31 as compared to the previous trading day's close of $174.70.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $16.5 billion and is part of the drugs industry. The company has a P/E ratio of 88.5, above the S&P 500 P/E ratio of 17.7. Shares are up 214.6% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

2. As of noon trading, Amgen ( AMGN) is down $0.54 (-0.6%) to $86.44 on light volume Thus far, 956,089 shares of Amgen exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $85.46-$86.77 after having opened the day at $86.77 as compared to the previous trading day's close of $86.98.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $67.0 billion and is part of the drugs industry. The company has a P/E ratio of 15.6, below the S&P 500 P/E ratio of 17.7. Shares are up 35.5% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, reasonable valuation levels and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Amgen Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

1. As of noon trading, Gilead ( GILD) is down $0.66 (-0.9%) to $73.99 on light volume Thus far, 2.5 million shares of Gilead exchanged hands as compared to its average daily volume of 8.4 million shares. The stock has ranged in price between $73.02-$74.94 after having opened the day at $74.55 as compared to the previous trading day's close of $74.65.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $57.2 billion and is part of the drugs industry. The company has a P/E ratio of 23.4, above the S&P 500 P/E ratio of 17.7. Shares are up 84.4% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Gilead Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null